EFEric Farfour

Eric Farfour

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Eric Farfour has a total of 306 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Current knowledge and perspectives on the emerging Inquilinus limosus pathogen

    by Eric Farfour, Audrey Brisebarre, Stéphane Corvec, Thomas Guillard

    SUMMARY: Inquilinus limosus is a nonfermentative Gram-negative rod that has been reported as an emergent pathogen, particularly in chronic respiratory diseases. I. limosus was first isolated from the airways of a lung transplant patient suffering from cystic fibrosis (CF). As I. limosus is almost exclusively recovered from the airways of CF patients, its identification may be challenging for non-CF specialists. Indeed, I. limosus is mainly isolated from the airways of CF patients, and its pathogenesis and treatments are still debated. We have extensively reported and reviewed the different clinical cases described in the literature, the identification methods used, and the antimicrobial susceptibility testing performed. Therefore, we provide here an exhaustive description of the phenotypic features and antimicrobial susceptibilities of I. limosus . Only seven I. limosus genomes are currently available in public databases. These genomes are not fully assembled and therefore allow only partial genomic analyses, which could not unveil antimicrobial resistance determinants or virulence factors. They are approximately 7 Mb in size and encode between 6,036 and 7,483 genes. Given that the available genomes are incomplete, our genomic analyses are still limited and would undoubtedly benefit from further fully sequenced and annotated genomes to provide additional information on the antibiotic resistance and pathogenesis of I. limosus . We anticipate that our review will be a starting point for more genome sequencing studies, as well as epidemiological studies, to provide additional information on I. limosus for better management of patients.

  • Open Access

    Temocillin for non-urinary tract infections caused by AmpC-producing Enterobacterales: Is it a feasible option?

    by Christel Mamona-Kilu, Bui Hai Hoang, Eric Farfour, Aurélien Dinh

  • Open Access

    Oligella spp.: A systematic review on an uncommon urinary pathogen

    by Eric Farfour, Marc Vasse, Alexandre Vallée

    Background: Oligella is an uncommon Gram-negative coccobacillus that was first thought to belong to the urogenital tract. The genus Oligella comprises two species that were recovered from various samples worldwide. Methods: We perform a systematic review focusing on Oligella microbiological characteristics, habitat, role in Human microbiome and infection, and antimicrobial susceptibility. Results: In humans, Oligella is mainly found as part of the microbiome of individuals with predisposing conditions. Oligella were also associated with invasive infections in patients with underlying diseases. Nevertheless, their prevalence remains to determine. Oligella culture requires up to 48 h on agar media in vitro, while urinary samples are usually incubated for 24 h. Consequently, microbiologists should be prompt to prolong the incubation of agar media when the direct examination showed Gram-negative coccobacilli. Oligella is accurately identified using MALDI-TOF mass spectrometry, but biochemical methods often provided inconsistent results. Specific guidelines for antimicrobial susceptibility testing of Oligella lack but the incubation could require up to 48 h of incubation. In contrast to O. urethralis, which is susceptible to third-generation cephalosporin, O. ureolytica is likely resistant to numerous antimicrobials. Genectic determinants of resistance were identified for beta-lactams and aminoglycosides. Conclusion: Oligella is an uncommon pathogen that can be underrecognized. Microbiologists should be prompt to prolong the incubation of agar media plated with urines when the direct examination showed Gram-negative coccobacilli. Carbapenems should probably be given for the empirical treatment.


  • Determinants of radiological patterns and severity in immunocompromised adults with Metapneumovirus infection

    by A. Al-Hamoud, N. Pansu, A.-L. Brun, N. Etienne, E. Farfour, V. Avettand-Fenoel, C. Rouzaud, A. Roux, F. Suarez, H. Salvator, et al.


  • Comparison of the Alinity M STI with the GeneXpert CT/NG for the detection of sexually transmitted microorganisms

    by Eric Farfour, Cyril Kitous, David Zucman, Pauline Touche, Kewin Panel, Erwan Fourn, Marc Vasse


  • Open Access

    Can Haematological Parameters Discriminate COVID-19 from Influenza?

    by Sahar Gnaba, Dmitry Sukhachev, Tiffany Pascreau, Félix Ackermann, Frédérique Delcominette, Florence Habarou, Aurélie Védrenne, Emilie Jolly, Elena Sukhacheva, Eric Farfour, et al.

    Symptoms of COVID-19 are similar to the influenza virus, but because treatments and prognoses are different, it is important to accurately and rapidly differentiate these diseases. The aim of this study was to evaluate whether the analysis of complete blood count (CBC), including cellular population (CPD) data of leukocytes and automated flow cytometry analysis, could discriminate these pathologies. In total, 350 patients with COVID-19 and 102 patients with influenza were included between September 2021 and April 2022 in the tertiary hospital of Suresnes (France). Platelets were lower in patients with influenza than in patients with COVID-19, whereas the CD16pos monocyte count and the ratio of the CD16pos monocytes/total monocyte count were higher. Significant differences were observed for 9/56 CPD of COVID-19 and flu patients. A logistic regression model with 17 parameters, including among them 11 CPD, the haemoglobin level, the haematocrit, the red cell distribution width, and B-lymphocyte and CD16pos monocyte levels, discriminates COVID-19 patients from flu patients. The sensitivity and efficiency of the model were 96.2 and 86.6%, respectively, with an area under the curve of 0.862. Classical parameters of CBC are very similar among the three infections, but CPD, CD16pos monocytes, and B-lymphocyte levels can discriminate patients with COVID-19.

  • Open Access

    Impact of revised breakpoints on the categorization of susceptibility of Enterobacterales to temocillin

    by Eric Farfour, Cécile Le Brun, Nicolas Degand, Emeline Riverain, Aurélien Dinh, Thierry Timores, Christel Mamona, Alexandre Vallée, Marc Vasse

    Background: To harmonize with the EUCAST breakpoints, the French Society of Microbiology introduced a change in the inhibition diameter breakpoint (17 mm versus 20 mm previously) of temocillin. We assessed the impact of the new breakpoints on categorizing susceptibility of Enterobacterales to temocillin. Methods: This was a multicentric retrospective study including all Enterobacterales isolates routinely tested for temocillin susceptibility with the disc diffusion method between 1 January 2016 and 31 July 2022 in four centres. Categorization using the breakpoints of 20 mm (French guidelines CA-SFM/EUCAST 2020 v.1.1) and 17 mm (French guidelines CA-SFM/EUCAST 2021 v1.0 and EUCAST guidelines v11.0) was performed. Results: Overall, 36 416 Enterobacterales isolates were included. The overall rate of temocillin resistance decreased from 11.3% to 4.7% (relative difference of 58.5%) when using the 17 mm breakpoint instead of the 20 mm breakpoint, respectively. The relative change ranged from −44.0% in Klebsiella aerogenes to −72.7% in Klebsiella oxytoca. The median inhibition diameter was 23 mm (IQR 21–25). The isolates with a diameter of 20 mm appeared overrepresented, whereas those with a diameter of 18 and 19 mm were underrepresented. We therefore reviewed the diameters between 18 and 21 mm of 273 isolates. Thirty-two (11.7%) of them categorized as susceptible at first measure were controlled resistant at second measure. Conclusions: The new breakpoint induced a decrease in the rate of isolates categorized as resistant to temocillin, increasing therapeutic choice including for Extended-spectrum beta-lactamase-producing Enterobacterales (ESBL-PE). We suggest the bias in measuring the inhibition diameter is probably related to the fact that temocillin is considered remarkably stable against broad-spectrum β-lactamases.


  • Impact of COVID-19 pandemic on blood culture practices and bacteremia epidemiology

    by Eric Farfour, Valentin Clichet, Gauthier Péan de Ponfilly, Etienne Carbonnelle, Marc Vasse


  • Open Access

    Rarely Encountered Gram-Negative Rods and Lung Transplant Recipients: A Narrative Review

    by Eric Farfour, Antoine Roux, Edouard Sage, Hélène Revillet, Marc Vasse, Alexandre Vallée

    The respiratory tract of lung transplant recipients (LTR) is likely to be colonized with non-fermentative Gram-negative rods. As a consequence of the improvements in molecular sequencing and taxonomy, an increasing number of bacterial species have been described. We performed a review of the literature of bacterial infections in LTR involving non-fermentative Gram-negative rods with exclusion of Pseudomonas aeruginosa, Stenotrophomonas maltophilia, Achromobacter spp. and Burkholderia spp. Overall, non-fermenting GNR were recovered from 17 LTR involving the following genera: Acetobacter, Bordetella, Chryseobacterium, Elizabethkinga, Inquilinus, and Pandoraea. We then discuss the issues raised by these bacteria, including detection and identification, antimicrobial resistance, pathogenesis, and cross-transmission.